The US Food and Drug Administration (FDA) has granted humanitarian device exemption marketing approval to BSD Medical’s BSD-2000 hyperthermia system

The BSD-2000 is approved for use along with radiation therapy for the treatment of cervical cancer patients.

The hyperthermia system generates localised therapeutic heating by applying radiofrequency energy.

BSD Medical CEO Harold Wolcott said the approval provides clinicians with a new device for cervical cancer patients who are candidates for radiation therapy but ineligible for chemotherapy.